Neurological Disorder Diagnostics Treatment Market Size, Share, Opportunities, And Trends By Type of Disorder (Neurodegenerative Disorders, Neuromuscular Disorders, Spinal Disorders, Peripheral Nerve Disorder), By Technology (Neurodegenerative Disorders, Neuromuscular Disorders, Spinal Disorders, Peripheral Nerve Disorder), By End User (Hospitals & Clinics, Diagnostic Centers, Others), And By Geography - Forecasts from 2025 To 2030
- Published : Jan 2025
- Report Code : KSI061617236
- Pages : 148
The Neurological disorder diagnostics treatment market is expected to grow at a CAGR of 4.76%, reaching a market size of US$18.903 billion in 2030 from US$14.340 billion in 2025
Neurological disorders are conditions that affect nervous system functioning, including the brain, spinal cord, and nerves. The disorder includes neurodegenerative conditions like Alzheimer's, multiple sclerosis, and Parkinson’s disease; neuromuscular conditions such as muscular dystrophy and amyotrophic lateral sclerosis; Spine conditions like Spina Bifida, spinal cord injury, spinal muscular atrophy; and peripheral nerve conditions like peripheral neuropathy, carpel tunnel syndrome among some other diseases.
The neurological disorder diagnostics market consists of all the tools, techniques, devices, products, and services used to diagnose neurological disorders, such as Alzheimer's, migraines, and sclerosis, including magnetic resonance imaging, computed tomography, neuroimaging biomarkers, ultrasound systems, blood & cerebrospinal fluid tests for biomarkers, genetic testing, wearable and portable devices and software for analyzing data among others. Hospitals, clinics, and diagnostic centers are covered under the market.
Several factors contribute to the growing neurological disorder diagnostic market. There is a rising prevalence of neurological diseases like Alzheimer's, dementia, Parkinson’s disease, and others, along with the increasing number of brain injuries due to rising cases of accidents, boosting market expansion. Governments, NGOs, and other institutions are also creating awareness among people to prioritize early screening of neurological health, propelling the demand for early diagnosis. Further, increased research and development investment has led to advanced diagnostics technology and processes, resulting in market expansion. This is further aggravated by the increasing adoption of artificial intelligence and machine learning technologies boosting market growth by offering more accurate data and data analysis. Moreover, the government's increasing healthcare investment, particularly driven by emerging countries, is propelling market growth. Thus, the market is expanding with the opportunities for expansion and innovation.
What are the Neurological Disorder Diagnostics Treatment Market drivers?
- Rising Prevalence of neurological disorders
The world is witnessing a substantial rise in the number of neurological disorders due to several reasons, such as the changing lifestyle characterized by stress, mental health issues, reduced physical activity and over-reliance on digital technology, an aging population, increasing pollution and toxins in the environment, among others. It is leading to increased cases of diseases like Alzheimer's, Parkinson's disease, etc., growing the demand for neurological disorder diagnostics tools and techniques. It is evident from the data released by the Alzheimer’s Association, which states that roughly 4.8 million Americans aged 65 have dementia due to Alzheimer's disease. A total of 6.9 million people in America have dementia.
- Increasing advancement in technology for diagnosing neurological disorder
Neurological disorders are witnessing significant advancements in diagnostic technologies and processes, leading to market growth. These innovations are addressing previously unmet needs by enabling more efficient and accurate diagnoses, such as advancement in technologies like MRI, CT scans, PET scans, fMRI, Genetic testing, and others, thereby improving patient outcomes and meeting the rising demand for precise and timely neurological care. For example, advancements in gene therapy, such as vector targeting through capsid modifications, are increasing the efficiency of transduction and delivering it to a wider area. Emerging technologies like artificial intelligence and machine learning are being used to analyze complex data sets for fast and accurate detection of disorders. AI is being leveraged in MRI to detect subtle abnormalities in conditions like brain tumors, strokes, etc.
What are the restraints of Neurological Disorder Diagnostics Treatment Market?
- The high cost of advanced diagnostic techniques limits its market expansion to low- and middle-income countries
Neurological disorder diagnostic techniques, tools, and devices are costly, and the advanced tools and techniques are highly expensive. An average MRI scan ranges from $1600 to $8400 in the US, depending on the provider and other factors. The maintenance and operational cost of tools and machines, along with the cost associated with skilled professionals needed for the diagnosis process, makes the overall cost expensive for the masses, particularly for those who belong to low and middle income. Countries with low and middle incomes lack the necessary health infrastructure, including neurological disorder diagnostics, limiting market expansion. Patients, as well as hospitals & diagnostic centers, find it hard to afford these advanced techniques, thus limiting access to a large chunk of the population. There is a need for cost-effective alternatives along with increased investment by governments and private players.
Segment analysis of the Neurological Disorder Diagnostics Treatment Market:
- By Application, hospitals and clinics will continue to hold the largest segment
By end-user, the neurological disorder diagnostics market is segmented into hospitals & clinics, diagnostic centers, and others. During the forecast period, hospitals and clinics will continue to dominate the market.
Hospitals and clinics are the largest end-users of neurological disorder diagnosis as hospitals are crucial for healthcare infrastructure and play a central role in patient care. These healthcare facilities require advanced diagnostic tools to accurately identify and treat conditions like Alzheimer's, Parkinson's, epilepsy, etc. As these advanced infrastructures for diagnosis are expensive and need infrastructure, hospitals are often equipped with diagnostic equipment and skilled professionals, and their capacity for conducting the diagnosis, making hospitals & clinics hold the largest market share.
What key geographical trends are shaping the Neurological Disorder Diagnostics Treatment Market?
- Asia-Pacific will be the fastest-growing region during the forecast period
The neurological disorder diagnostics market is segmented by geography into North America, South America, Europe, the Middle East and Africa, and Asia-Pacific. During the forecast period, Asia-Pacific will be the fastest-growing region in the neurological disorder diagnostics market. Meanwhile, North America will continue dominating the market in the coming years. Europe will also have a significant market share in the forecast period.
The Asia Pacific region will be the fastest-growing market during the forecast period. This robust growth in the region is attributed to the growing economies of Asia-Pacific, like China, South Korea, and India. This is driving continued healthcare infrastructure development in the region, resulting in growth in associated markets like the neurological disorder diagnostic market. The increasing prevalence of neurological disorders is driving the demand for diagnostics, thus propelling the market growth.
Meanwhile, the North American market is estimated to hold a significant market share in neurological disorders diagnostics. The advanced healthcare infrastructure in countries like the United States drives this dominance. The high prevalence of neurological disorders is driving this market expansion, with 6.9 million dementia patients from Alzheimer's in 2024. Further, the government is making significant investments and private players are driving its continued regional expansion.
Recent developments in the Neurological Disorder Diagnostics Treatment Market:
- In April 2024, neuroClues®, a medtech company specializing in neurodegenerative disease diagnostics, successfully closed a €5 million funding round, bringing its total funding to €12 million. The investment will support product development and expansion into European and North American markets.
- In November 2024, PTC Therapeutics announced the FDA's accelerated approval of KEBILIDI™, a gene therapy for AADC deficiency, the first gene therapy administered directly to the brain. KEBILIDI received accelerated approval based on the safety and clinical efficacy findings in the ongoing global clinical trial of the gene therapy.
Neurological Disorder Diagnostics Treatment Market Scope:
| Report Metric | Details |
| Neurological Disorder Diagnostics Treatment Market Size in 2025 | US$14.340 billion |
| Neurological Disorder Diagnostics Treatment Market Size in 2030 | US$18.903 billion |
| Growth Rate | CAGR of 4.76% |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Forecast Unit (Value) | USD Billion |
| Segmentation |
|
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| List of Major Companies in Neurological Disorder Diagnostics Treatment Market |
|
| Customization Scope | Free report customization with purchase |
The Neurological Disorder Diagnostics Treatment Market is analyzed into the following segments:
- By Type of Disorder
- Neurodegenerative Disorders
- Neuromuscular Disorders
- Spinal Disorders
- Peripheral Nerve Disorder
- By Technology
- Imaging Techniques
- In Vitro Diagnostic Techniques
- By End-User
- Hospitals & Clinics
- Diagnostic Centers
- Others
- By Geography
- North America
- USA
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- United Kingdom
- Germany
- France
- Spain
- Others
- Middle East and Africa
- Saudi Arabia
- UAE
- Others
- Asia Pacific
- China
- Japan
- South Korea
- Australia
- India
- Indonesia
- Thailand
- Others
- North America
Frequently Asked Questions (FAQs)
The neurological disorder diagnostics treatment market is expected to reach a total market size of US$18.903 billion by 2030.
Neurological Disorder Diagnostics Treatment Market is valued at US$14.340 billion in 2025.
The global neurological disorder diagnostics treatment market is expected to grow at a CAGR of 4.76% during the forecast period.
Rising neurological disorder prevalence, tech advancements, AI adoption, and increased healthcare investment are driving market growth.
The Asia-Pacific region is anticipated to hold a significant share of the neurological disorder diagnostics treatment market.
1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key Benefits to the Stakeholder
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Processes
3. EXECUTIVE SUMMARY
3.1. Key Findings
3.2. CXO Perspective
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Analyst View
5. NEUROLOGICAL DISORDER DIAGNOSTICS TREATMENT MARKET BY TYPE OF DISORDER
5.1. Introduction
5.2. Neurodegenerative Disorders
5.3. Neuromuscular Disorders
5.4. Spinal Disorders
5.5. Peripheral Nerve Disorder
6. NEUROLOGICAL DISORDER DIAGNOSTICS TREATMENT MARKET BY TECHNOLOGY
6.1. Introduction
6.2. Imaging Techniques
6.3. In Vitro Diagnostic Techniques
7. NEUROLOGICAL DISORDER DIAGNOSTICS TREATMENT MARKET BY END-USER
7.1. Introduction
7.2. Hospitals & Clinics
7.3. Diagnostic Centers
7.4. Others
8. NEUROLOGICAL DISORDER DIAGNOSTICS TREATMENT MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. By Type of Disorder
8.2.2. By Technology
8.2.3. By End-User
8.2.4. By Country
8.2.4.1. USA
8.2.4.2. Canada
8.2.4.3. Mexico
8.3. South America
8.3.1. By Type of Disorder
8.3.2. By Technology
8.3.3. By End-User
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.2. Argentina
8.3.4.3. Others
8.4. Europe
8.4.1. By Type of Disorder
8.4.2. By Technology
8.4.3. By End-User
8.4.4. By Country
8.4.4.1. United Kingdom
8.4.4.2. Germany
8.4.4.3. France
8.4.4.4. Spain
8.4.4.5. Others
8.5. Middle East and Africa
8.5.1. By Type of Disorder
8.5.2. By Technology
8.5.3. By End-User
8.5.4. By Country
8.5.4.1. Saudi Arabia
8.5.4.2. UAE
8.5.4.3. Others
8.6. Asia Pacific
8.6.1. By Type of Disorder
8.6.2. By Technology
8.6.3. By End-User
8.6.4. By Country
8.6.4.1. China
8.6.4.2. Japan
8.6.4.3. South Korea
8.6.4.4. Australia
8.6.4.5. India
8.6.4.6. Indonesia
8.6.4.7. Thailand
8.6.4.8. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. GE Healthcare
10.2. Siemens Healthcare
10.3. FUJIFILM Holdings Corporation
10.4. Koninklijke Philips N.V.
10.5. Thermo Fisher Scientific Inc.
10.6. Masimo
10.7. Medtronic
10.8. Abbott Laboratories
GE Healthcare
Siemens Healthcare
FUJIFILM Holdings Corporation
Koninklijke Philips N.V.
Thermo Fisher Sxcientific Inc.
Masimo
Medtronic
Abbott Laboratories
Related Reports
| Report Name | Published Month | Download Sample |
|---|---|---|
| Tissue Diagnostic Market Size & Share: Industry Report, 2023-2028 | Aug 2023 | |
| In Vitro Diagnostics Market Forecast 2024-2029 | Free Sample | Aug 2024 | |
| Critical Care Diagnostics Market Size & Share: Report, 2023-2028 | Mar 2023 | |
| Cancer Diagnostics Market Size & Share: Industry Report, 2023-2028 | Sep 2023 | |
| Point of Care Diagnostic Size & Share: Industry Report, 2022-2027 | Dec 2022 |
